Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
79 participants
OBSERVATIONAL
2018-11-01
2019-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Empirical Antifungal Treatment in ICUS
NCT01773876
Impact of a Loading Dose of Caspofungin in Invasive Candidiasis in ICU Patients
NCT02413892
Pharmacokinetics of Micafungin in Patients of Intensive Care Units
NCT02164890
Anidulafungin Candidemia/Invasive Candidiasis Intensive Care Study
NCT00689338
Candida in the Respiratory Tract Secretions of Critically Ill Patients and The Efficacy of Antifungal Treatment
NCT00934934
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Echinocandin group
Echinocandin group is the group of patients who received echinocandins as first-line therapy for candidemia
Echinocandin treatment
Patients received echinocandins as a first-line therapy after candidemia diagnosis according to the standard of care
Triazole group
Triazole group is the group of patients who received triazoles as first-line therapy for candidemia
Triazole treatment
Patients received triazoles as a first-line therapy after candidemia diagnosis according to the standard of care.
Candidemia was defined as at least one blood culture positive for Candida.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Echinocandin treatment
Patients received echinocandins as a first-line therapy after candidemia diagnosis according to the standard of care
Triazole treatment
Patients received triazoles as a first-line therapy after candidemia diagnosis according to the standard of care.
Candidemia was defined as at least one blood culture positive for Candida.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients without antifungal treatment
* Patients who received antifungal therapy for more than two days before candidemia diagnosis
* Patients receiving liposomal amphotericin b or multiple antifungal agents as first-line therapy
* Patients who received less than 4 days of antifungal therapy after candidemia diagnosis
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospices Civils de Lyon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospices Civils de Lyon, Hôpital de la Croix-Rousse
Lyon, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CRC_GHN_2019_001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.